Global Orally Disintegrating Tablet Market By Drug Class (Anti-Epileptics, Anti-Psychotics, Anti-Hypertensives, Proton Pump Inhibitors, Other Drug Classes) By Disease Indication (CNS Diseases, CVS Disorders, GI Diseases, Other Disease Indications) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: Jan 2024
- Report ID: 13004
- Number of Pages: 304
- Format:
-
-
- 1. Orally Disintegrating Tablet Market Introduction
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 2. Executive Summary
- 2.1. Key Findings by Major Segments
- 2.2. Top strategies by Major Players
- 3. Global Orally Disintegrating Tablet Market Overview
- 3.1. Orally Disintegrating Tablet Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Opportunities
- 3.1.3. Restraints
- 3.1.4. Challenges
- 3.2. PESTLE Analysis
- 3.3. Opportunity Map Analysis
- 3.4. PORTER'S Five Forces Analysis
- 3.5. Market Competition Scenario Analysis
- 3.6. Product Life Cycle Analysis
- 3.7. Opportunity Orbits
- 3.8. Manufacturer Intensity Map
- 3.1. Orally Disintegrating Tablet Market Dynamics
- 4. Global Orally Disintegrating Tablet Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
- 4.1. Global Orally Disintegrating Tablet Market Analysis by Type: Introduction
- 4.2. Market Size and Forecast by Region
- 4.3. Anti-Psychotics Drug
- 4.4. Anti-Epileptics Drug
- 4.5. Other
- 5. Global Orally Disintegrating Tablet Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
- 5.1. Global Orally Disintegrating Tablet Market Analysis by Application: Introduction
- 5.2. Market Size and Forecast by Region
- 5.3. CNS Diseases
- 5.4. Gastrointestinal Diseases
- 5.5. CVS Diseases
- 5.6. Other
- 6. Global Orally Disintegrating Tablet Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
- 6.1. North America
- 6.1.1. North America Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.1.1.1. US
- 6.1.1.2. Canada
- 6.1.1.3. Mexico
- 6.1.1. North America Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.2.1. Europe
- 6.2.1. Europe Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.2.1.1. Germany
- 6.2.1.2. France
- 6.2.1.3. UK
- 6.2.1.4. Russia
- 6.2.1.5. Italy
- 6.2.1.6. Spain
- 6.2.1.7. Rest of Europe
- 6.2.1. Europe Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.3. Asia-Pacific
- 6.3.1. Asia-Pacific Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.3.1.1. China
- 6.3.1.2. Japan
- 6.3.1.3. Korea
- 6.3.1.4. India
- 6.3.1.5. Rest of Asia
- 6.3.1. Asia-Pacific Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.4. Latin America
- 6.4.1. Latin America Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.4.1.1. Brazil
- 6.4.1.2. Argentina
- 6.4.1.3. Rest of Latin America
- 6.4.1. Latin America Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.5. Middle East and Africa
- 6.5.1. Middle East and Africa Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.5.1.1. GCC
- 6.5.1.2. South Africa
- 6.5.1.3. Israel
- 6.5.1.4. Rest of MEA
- 6.5.1. Middle East and Africa Orally Disintegrating Tablet Market: Regional Trend Analysis
- 6.1. North America
- 7. Global Orally Disintegrating Tablet Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 7.1. Market Share Analysis
- 7.2. Company Profiles
- 7.3. Teva
- 7.3.1. Company Overview
- 7.3.2. Financial Highlights
- 7.3.3. Product Portfolio
- 7.3.4. SWOT Analysis
- 7.3.5. Key Strategies and Developments
- 7.4. Merck
- 7.4.1. Company Overview
- 7.4.2. Financial Highlights
- 7.4.3. Product Portfolio
- 7.4.4. SWOT Analysis
- 7.4.5. Key Strategies and Developments
- 7.5. Mylan
- 7.5.1. Company Overview
- 7.5.2. Financial Highlights
- 7.5.3. Product Portfolio
- 7.5.4. SWOT Analysis
- 7.5.5. Key Strategies and Developments
- 7.6. Pfizer
- 7.6.1. Company Overview
- 7.6.2. Financial Highlights
- 7.6.3. Product Portfolio
- 7.6.4. SWOT Analysis
- 7.6.5. Key Strategies and Developments
- 7.7. Johnson and Johnson
- 7.7.1. Company Overview
- 7.7.2. Financial Highlights
- 7.7.3. Product Portfolio
- 7.7.4. SWOT Analysis
- 7.7.5. Key Strategies and Developments
- 7.8. GSK
- 7.8.1. Company Overview
- 7.8.2. Financial Highlights
- 7.8.3. Product Portfolio
- 7.8.4. SWOT Analysis
- 7.8.5. Key Strategies and Developments
- 7.9. Otsuka
- 7.9.1. Company Overview
- 7.9.2. Financial Highlights
- 7.9.3. Product Portfolio
- 7.9.4. SWOT Analysis
- 7.9.5. Key Strategies and Developments
- 7.10. Eli Lilly and Company
- 7.10.1. Company Overview
- 7.10.2. Financial Highlights
- 7.10.3. Product Portfolio
- 7.10.4. SWOT Analysis
- 7.10.5. Key Strategies and Developments
- 7.11. AstraZeneca
- 7.11.1. Company Overview
- 7.11.2. Financial Highlights
- 7.11.3. Product Portfolio
- 7.11.4. SWOT Analysis
- 7.11.5. Key Strategies and Developments
- 7.12. Bristol-Myers Squibb
- 7.12.1. Company Overview
- 7.12.2. Financial Highlights
- 7.12.3. Product Portfolio
- 7.12.4. SWOT Analysis
- 7.12.5. Key Strategies and Developments
- 7.13. Conquer
- 7.13.1. Company Overview
- 7.13.2. Financial Highlights
- 7.13.3. Product Portfolio
- 7.13.4. SWOT Analysis
- 7.13.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- 1. Orally Disintegrating Tablet Market Introduction
-
- AstraZeneca plc.
- Mylan N.V.
- Pfizer Inc Company Profile
- Johnson & Johnson Services, Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bausch Health
- GlaxoSmithKline plc.
- Sun Pharmaceutical Industries Ltd.
- Bayer AG Company Profile
- Eli Lily and Company
- Dr. Reddys Laboratories Ltd Company Profile
- Takeda Pharmaceutical Company Limited
- Other Key Players
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |